MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/13872877251376694

Медицинская библиотека · Journal of Alzheimer's disease : JAD · 2025

Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting.

Chatterjee Pratishtha, Ivanic Svetlana, Southon Adam, McCarthy Claire, Patel Sheila K, Christensen Maja, Darby David, Bush Ashley I, Ayton Scott, Werden Emilio, Brodtmann Amy

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BackgroundPlasma p-tau217 shows exceptional diagnostic performance for Alzheimer's disease (AD) in cohort studies. Recent real-world studies support its validity in more diverse populations.ObjectiveTest the performance of plasma p-tau217 in representative real-world early-onset cognitive disorders patients.Methods118 adult patients with cognitive complaints or potential neurodegenerative diseases (ND) from a single healthcare network in Melbourne, Australia, were categorized into three groups based on clinical diagnosis: non-ND (n = 52), early-onset AD (EOAD, n = 39), and non-AD ND (other-ND, n = 27). Plasma p-tau217 was measured using the Simoa® ALZpath p-Tau 217 Assay.ResultsPlasma p-tau217 was elevated in EOAD (mean ± SD: 1.13 ± 0.51) compared with non-ND (0.31 ± 0.27, p = 5.43e-23) and other-ND (0.23 ± 0.10, p = 9.65e-21). ROC analysis revealed excellent diagnostic performance, with AUCs of 0.944 [95% CI:0.893-0.996] for EOAD versus non-ND and 0.984 [0.962-1.000] for EOAD versus other-ND. Using a binary cut-off (p-tau217 > 0.42 pg/mL), 17% non-ND, 95% EOAD and 7% other-ND were A + . Using a two-tiered cut-off approach (0.40 pg/mL > p-tau217 > 0.63 pg/mL), 4% non-ND, 94% EOAD and 0% other-ND were A + . 10% of participants (n = 12) were within the intermediate range. Using the binary cut-off of p-tau217 > 0.64 pg/mL for T+, 100% EOAD and 0% other-ND A + participants, defined by the two-tiered cut-off approach, were T + . No associations of p-tau217 with age, sex, or ethnicity were found within ND groups. P-tau217 was elevated in individuals with severely impaired renal function.ConclusionsThe findings support the clinical utility of plasma p-tau217 in the real-world diagnostic evaluation of EOAD. However, careful interpretation of false positive results in patients with severe renal impairment is required.

Для цитирования: Chatterjee Pratishtha, Ivanic Svetlana, Southon Adam, McCarthy Claire, Patel Sheila K, Christensen Maja, Darby David, Bush Ashley I, Ayton Scott, Werden Emilio, Brodtmann Amy. Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting.. Journal of Alzheimer's disease : JAD. 2025. DOI: 10.1177/13872877251376694.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.